Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Autor: Bertrand L. Kasiske, Manjula Kurella Tamura, Kathryn Griffith, Marie Evans, Mustafa Arici, Min Jun, David C. Wheeler, Brenda R. Hemmelgarn, Edgar V. Lerma, Hiddo J.L. Heerspink, Michael Cheung, Kamyar Kalantar-Zadeh, Matthew T. James, Wolfgang C. Winkelmayer, Elke Schäffner, Adeera Levin, Shuchi Anand, Bénédicte Stengel, Kitty J. Jager, Zofia Das-Gupta, Paul E. Stevens, Ali K. Abu-Alfa, Jamie P. Dwyer, Angela Yee-Moon Wang, Amy W. Williams, Nisha Bansal, Dorry L. Segev, Edmund J. Lamb, David M. Charytan, Carol A. Pollock, Danielle M. Nash, Danilo Fliser, Roberto Pecoits-Filho, Miguel A. Vazquez, Kai-Uwe Eckardt, Juan Carlos Julián Mauro, Kate Huffman, Mintu P. Turakhia, Rafael Burgos-Calderon, Andrew S. Levey, Lesley A. Inker, Csaba P. Kovesdy, Marc Froissart, David Harris, Charles A. Herzog, Geoffrey A. Block, Shoshana H. Ballew, Bruce M. Robinson, Donal O'Donoghue, Sankar D. Navaneethan, Josef Coresh, Vera Krane, Francesca Tentori, Navdeep Tangri, Yusuke Tsukamoto, Peter Stenvinkel, John S. Gill, Gregorio T. Obrador, Morgan E. Grams, Marcello Tonelli
Přispěvatelé: Conference Participants, Abu-Alfa, A.K., Anand, S., Arici, M., Ballew, S.H., Block, G.A., Burgos-Calderon, R., Charytan, D.M., Das-Gupta, Z., Dwyer, J.P., Fliser, D., Froissart, M., Gill, J.S., Griffith, K.E., Harris, D.C., Huffman, K., Inker, L.A., Jager, K.J., Jun, M., Kalantar-Zadeh, K., Kasiske, B.L., Kovesdy, C.P., Krane, V., Lamb, E.J., Lerma, E.V., Levey, A.S., Levin, A., Julián Mauro, J.C., Nash, D.M., Navaneethan, S.D., O'Donoghue, D., Obrador, G.T., Pecoits-Filho, R., Robinson, B.M., Schäffner, E., Segev, D.L., Stengel, B., Stenvinkel, P., Tangri, N., Tentori, F., Tsukamoto, Y., Turakhia, M.P., Vazquez, M.A., Yee-Moon Wang, A., Williams, A.W., Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, ACS - Pulmonary hypertension & thrombosis
Rok vydání: 2017
Předmět:
medicine.medical_specialty
Consensus
Clinical Decision-Making
030232 urology & nephrology
Context (language use)
HEMODIALYSIS-PATIENTS
Disease
030204 cardiovascular system & hematology
urologic and male genital diseases
Kidney
Severity of Illness Index
OUTPUT CARDIAC-FAILURE
03 medical and health sciences
0302 clinical medicine
Risk Factors
medicine
Humans
Renal Insufficiency
Chronic

Intensive care medicine
CARDIOVASCULAR EVENTS
Evidence-Based Medicine
business.industry
INCIDENT HEART-FAILURE
STAGE RENAL-DISEASE
INSUFFICIENCY COHORT
RANDOMIZED CONTROLLED-TRIAL
medicine.disease
Prognosis
female genital diseases and pregnancy complications
Clinical trial
chronic kidney disease
kidney failure
prediction
prognosis
progression
supportive care
medicine.anatomical_structure
Decreased glomerular filtration rate
Nephrology
Heart failure
business
REDUCED EJECTION FRACTION
CLINICAL-TRIALS
Kidney disease
Cohort study
DIALYSIS INITIATION
Glomerular Filtration Rate
Zdroj: Kidney international, vol. 93, no. 6, pp. 1281-1292
Kidney International, 93(6), 1281-1292. ELSEVIER SCIENCE INC
Kidney international, 93(6), 1281-1292. Nature Publishing Group
ISSN: 1523-1755
0085-2538
Popis: Patients with severely decreased glomerular filtration rate (GFR) (i.e., chronic kidney disease [CKD] G4+) are at increased risk for kidney failure, cardiovascular disease (CVD) events (including heart failure), and death. However, little is known about the variability of outcomes and optimal therapeutic strategies, including initiation of kidney replacement therapy (KRT). Kidney Disease: Improving Global Outcomes (KDIGO) organized a Controversies Conference with an international expert group in December 2016 to address this gap in knowledge. In collaboration with the CKD Prognosis Consortium (CKD-PC) a global meta-analysis of cohort studies (n = 264,515 individuals with CKD G4+) was conducted to better understand the timing of clinical outcomes in patients with CKD G4+ and risk factors for different outcomes. The results confirmed the prognostic value of traditional CVD risk factors in individuals with severely decreased GFR, although the risk estimates vary for kidney and CVD outcomes. A 2- and 4-year model of the probability and timing of kidney failure requiring KRT was also developed. The implications of these findings for patient management were discussed in the context of published evidence under 4 key themes: management of CKD G4+, diagnostic and therapeutic challenges of heart failure, shared decision-making, and optimization of clinical trials in CKD G4+ patients. Participants concluded that variable prognosis of patients with advanced CKD mandates individualized, risk-based management, factoring in competing risks and patient preferences.
Databáze: OpenAIRE